@article{Surya Rau RVKM_2020, title={DEBT TO EQUITY RATIO AND ITS IMPACT ON PHARMA COMPANY PROFITABILITY}, volume={9}, url={http://www.modern-journals.com/index.php/ijma/article/view/146}, DOI={10.17762/ijma.v9i3.146}, abstractNote={<p>In a capitalistic structure, there are numerous risks and factors that can play a role in the outcome of business. Government policies also play a major role in the outcome of business activities.</p> <p>The policies that are laid down by the business-friendly governments are mostly in accordance with the aim of an increased level of economic activities in the countries. However, the business activities or the economic results shown by the organizations are determined by numerous layers of performance indications. One such indication is that of the Debt Equity Ratio or DER of the organizations. The debt equity ratio of a company is calculated by dividing the liabilities that the company poses in its account to the equity that is invested in the company through its shareholders. In pharmaceutical companies, the onus is on the ability of the CEO of the firm to continuously encourage and enable the investors to rely on their money invested in the organization in various times. There are many studies that provide indications and suggestions regarding the performance of the CEO of the organizations in the matter of DER. Many of these studies suggest that DER is a bigger factor in case of pharmaceutical companies than in case of an average multinational corporation.</p>}, number={3}, journal={International Journal of Modern Agriculture}, author={Surya Rau RVKM}, year={2020}, month={Oct.}, pages={297-302} }